COMP360
- Molecule class
- synthetic psilocybin (company description)
- Mechanism
- Not independently verified.
- Indication
- treatment-resistant depression; PTSD programme separate
- Sponsor geography
- UK
- Next catalyst
- Final rolling NDA submission, by 2026-12-31
- Partner
- US Department of Veterans Affairs (PIVOT study, drug donation and training support only)
- IP status
- Not checked. Recorded as unchecked rather than left blank.
The catalyst above is recorded as reported, not verified. It is this publication's reading of the company's guidance, not a date the company has published.
euclinicaltrials.euregistryverified 2026-08-25
Registered trials
PHASE3 · Treatment Resistant Depression · COMPLETED · United States
clinicaltrials.govctgov registryverified 2026-08-31
PHASE3 · Treatment Resistant Depression · ACTIVE_NOT_RECRUITING · Canada, Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-08-31
Therapeutic confirmatory (Phase III) · Treatment-resistant depression · Authorised · Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden
euclinicaltrials.euctis registryverified 2026-08-31
In the briefing
Issues tagged COMPASS, the owner of this asset.
- No. 1
Psychedelic Brief